Transcriptomic and Proteomic Profiles for Elucidating Cisplatin Resistance in Head-and-Neck Squamous Cell Carcinoma.

Autor: Garcia-Mayea Y; Biomedical Research in Cancer Stem Cells Group, Vall d'Hebron Research Institute (VHIR), 08035 Barcelona, Spain.; Departament de Genètica, Microbiologia i Estadística, Universitat de Barcelona, 08028 Barcelona, Spain., Benítez-Álvarez L; Departament de Genètica, Microbiologia i Estadística, Universitat de Barcelona, 08028 Barcelona, Spain., Sánchez-García A; Biomedical Research in Cancer Stem Cells Group, Vall d'Hebron Research Institute (VHIR), 08035 Barcelona, Spain., Bataller M; Biomedical Research in Cancer Stem Cells Group, Vall d'Hebron Research Institute (VHIR), 08035 Barcelona, Spain., Companioni O; Department of Biochemistry, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA., Mir C; Biomedical Research in Cancer Stem Cells Group, Vall d'Hebron Research Institute (VHIR), 08035 Barcelona, Spain., Benavente S; Biomedical Research in Cancer Stem Cells Group, Vall d'Hebron Research Institute (VHIR), 08035 Barcelona, Spain., Lorente J; Biomedical Research in Cancer Stem Cells Group, Vall d'Hebron Research Institute (VHIR), 08035 Barcelona, Spain., Canela N; Eurecat Centre Tecnològic de Catalunya-Centre for Omic Sciences (COS), Joint Unit University of Rovira i Virgili-EURECAT, 43204 Reus, Spain., Fernández-Rozadilla C; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain., Carracedo A; Fundación de Medicina Xenómica (SERGAS), 15706 Santiago de Compostela, Spain.; Grupo de Medicina Xenómica, Centro de Investigación de Red de Enfermedades Raras (CIBERER), CIMUS, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain., LLeonart ME; Biomedical Research in Cancer Stem Cells Group, Vall d'Hebron Research Institute (VHIR), 08035 Barcelona, Spain.; Spanish Biomedical Research Network Centre in Oncology, CIBERONC, Vall d'Hebron Research Institute (VHIR), Passeig Vall d´Hebron 119-129, 08035 Barcelona, Spain.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2022 Nov 09; Vol. 14 (22). Date of Electronic Publication: 2022 Nov 09.
DOI: 10.3390/cancers14225511
Abstrakt: To identify the novel genes involved in chemoresistance in head and neck squamous cell carcinoma (HNSCC), we explored the expression profiles of the following cisplatin (CDDP) resistant (R) versus parental (sensitive) cell lines by RNA-sequencing (RNA-seq): JHU029, HTB-43 and CCL-138. Using the parental condition as a control, 30 upregulated and 85 downregulated genes were identified for JHU029-R cells; 263 upregulated and 392 downregulated genes for HTB-43-R cells, and 154 upregulated and 68 downregulated genes for CCL-138-R cells. Moreover, we crossed-checked the RNA-seq results with the proteomic profiles of HTB-43-R (versus HTB-43) and CCL-138-R (versus CCL-138) cell lines. For the HTB-43-R cells, 21 upregulated and 72 downregulated targets overlapped between the proteomic and transcriptomic data; whereas in CCL-138-R cells, four upregulated and three downregulated targets matched. Following an extensive literature search, six genes from the RNA-seq ( CLDN1 , MAGEB2 , CD24 , CEACAM6 , IL1B and ISG15 ) and six genes from the RNA-seq and proteomics crossover ( AKR1C3 , TNFAIP2 , RAB7A , LGALS3BP , PSCA and SSRP1 ) were selected to be studied by qRT-PCR in 11 HNSCC patients: six resistant and five sensitive to conventional therapy. Interestingly, the high MAGEB2 expression was associated with resistant tumours and is revealed as a novel target to sensitise resistant cells to therapy in HNSCC patients.
Competing Interests: The authors declare no conflict of interest.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje